|
|
Volumn 102, Issue 3, 2006, Pages 419-420
|
|
Descriptions in the peer-reviewed literature of the results of phase 2 chemotherapy trials involving gynecologic malignancies: A call for greater objectivity
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTOSTATIC AGENT;
DOXORUBICIN;
OXALIPLATIN;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PATIENT;
CANCER RELAPSE;
CANCER SURVIVAL;
CLINICAL RESEARCH;
CLINICAL TRIAL;
DATA ANALYSIS;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
DRUG RESEARCH;
EDITORIAL;
EVIDENCE BASED PRACTICE;
GYNECOLOGIC CANCER;
HUMAN;
MEDICAL DECISION MAKING;
MEDICAL LITERATURE;
OVARY CANCER;
PEER REVIEW;
PRIORITY JOURNAL;
SURVIVAL RATE;
SURVIVAL TIME;
TREATMENT RESPONSE;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE II AS TOPIC;
EVIDENCE-BASED MEDICINE;
FEMALE;
GENITAL NEOPLASMS, FEMALE;
HUMANS;
PEER REVIEW, RESEARCH;
PROGNOSIS;
TREATMENT OUTCOME;
WRITING;
|
|
EID: 33748616000
PISSN: 00908258
EISSN: 10956859
Source Type: Journal
DOI: 10.1016/j.ygyno.2006.05.026 Document Type: Editorial |
|
Times cited : (1)
|
|
References (4)
|
